Stoke Therapeutics (STOK) Capital Expenditures Growth (1y) (2019 - 2026)
Powered by 
Analysis
Stoke Therapeutics (STOK) Capital Expenditures Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 1,133.33% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | -37.81% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 142.64% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 22,433.30% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -73.62% |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 1,183.12% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,183.12% |
| Mar 31, 2026 | 132.24% |
| Dec 31, 2025 | 452.38% |
| Sep 30, 2025 | 28.16% |
| Jun 30, 2025 | 234.78% |
| Mar 31, 2025 | 1,166.67% |
| Dec 31, 2024 | -81.66% |
| Sep 30, 2024 | -73.11% |
| Jun 30, 2024 | -89.98% |
| Mar 31, 2024 | -97.80% |
| Dec 31, 2023 | -44.01% |
| Sep 30, 2023 | -81.13% |
| Jun 30, 2023 | -32.70% |
| Mar 31, 2023 | -35.20% |
| Dec 31, 2022 | 51.48% |
| Sep 30, 2022 | 643.59% |
| Jun 30, 2022 | 31.15% |
| Mar 31, 2022 | 312.25% |
| Dec 31, 2021 | 200.00% |
| Sep 30, 2021 | 1.49% |